Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's diseaseFrank M. Ruemmele, Dan Turner, Anders Pærregaard et al.|Journal of Crohn s and Colitis|2014Cited by 1.1k
Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel DiseaseJeffrey S. Hyams, Meena Thayu, Marla C. Dubinsky et al.|Gastroenterology|2017Cited by 217
Nutrition in Pediatric Inflammatory Bowel DiseaseErasmo Miele, Annamaria Staiano, Raanan Shamir et al.|Journal of Pediatric Gastroenterology and Nutrition|2018Cited by 185
41 Serious Infections and Associated Risk Factors in Patients Receiving Infliximab and Immunotherapies for Children With Inflammatory Bowel Disease: Develop Registry DataRobert N. Baldassano, Harland S. Winter, Richard B. Colletti et al.|Gastroenterology|2013Cited by 8
833 Malignancies in Children Receiving Infliximab and Other Inflammatory Bowel Disease Therapies: An Inflammatory Bowel Disease Multicenter, Prospective, Long-Term Registry of Pediatric Patients (Develop) Registry DataRichard B. Colletti, Gigi Veereman, Salvatore Cucchiara et al.|Gastroenterology|2013Cited by 7